Royalty Pharma (RPRX)

Earnings in 2024 (TTM): HK$9.50 Billion

According to Royalty Pharma's latest financial reports the company's current earnings are HK$2.23 Billion. In 2023 the company made an earning of HK$14.68 Billion, an increase over its 2022 earnings that were of HK$3.25 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Royalty Pharma from 2019 to 2024

Annual earnings

Year	Earnings	Change
2024 (TTM)	HK$9.50 B	-35.27%
2023	HK$14.68 B	351.47%
2022	HK$3.25 B	-70.3%
2021	HK$10.94 B	-24.3%
2020	HK$14.46 B	-31.9%
2019	HK$21.23 B

Earnings for similar companies or competitors

Company	Earnings	Earnings differencediff.	Country
ANI Pharmaceuticals ANIP	HK$0.27 B	-97.08%	🇺🇸 USA
Abbott Laboratories ABT	HK$52.72 B	457.26%	🇺🇸 USA
Eli Lilly LLY	HK$78.96 B	734.54%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Earnings for Royalty Pharma (RPRX)

Earnings in 2024 (TTM): HK$9.50 Billion